Biotechnology
Antengene Announces Publication of Abstract on XPO1 Inhibitor Selinexor in Relapsed or Refractory Multiple Myeloma at ASCO 2021 and EHA 2021
SHANGHAI and HONG KONG, June 4, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-06-04 08:00
3105
Vela Diagnostics Announces Collaboration with the National Cancer Centre of Singapore to Refine Novel Cancer Therapy
SINGAPORE, June 4, 2021 /PRNewswire/ -- Vela Diagnostics announced a collaboration with the National Cancer Centre ofSingapore (NCCS) to develop a molecular diagnostic assay to predict individual patients' responses to a cancer therapy called Epidermal Growth Factor Receptor (EGFR) tyrosine kinas...
2021-06-04 08:00
2016
The first hormone replacement therapy for hypoparathyroidism in China obtains IND approval for Phase III clinical trial
1. VISEN Pharmaceuticals has obtained the investigational new drug (IND) approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) for the phase III China clinical trial (PaTHway China Trial) of TransCon PTH Solution for Injection (TransCon™ parathy...
2021-06-04 02:00
2151
RWDC Industries Appoints New Chief Financial Officer
Thomas Aebischer brings 18 years of public and private company CFO experience and proven leadership track record to RWDC ATHENS, Georgia and SINGAPORE, June 3, 2021 /PRNewswire/ -- RWDC Industries, a biotechnology company on a mission to replace single-use plastics through innovative and cost-ef...
2021-06-03 22:00
2318
Innovent and Lilly Jointly Announce the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with Gemcitabine and Platinum Chemotherapy as First-Line Therapy for People with Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major disease...
2021-06-03 17:09
4753
Peking University Biologics entering into Strategic Cooperation Agreement with Norwich Investment Limited
HONG KONG, June 3, 2021 /PRNewswire/ -- Peking University Biologics (hereinafter known as "PKU BIO") and Norwich Investment Limited (hereinafter known as "Norwich") announced today that both parties have entered into a Strategic Cooperation Agreement ("Agreement") to promote the business develop...
2021-06-03 16:29
2972
Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology's Medical Journal "Blood"
SAN FRANCISCO, U.S. and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major ...
2021-06-03 08:00
4741
Cell Care Joins the Generate Life Sciences Family to Create a Global Platform
The acquisition provides the companies with shared scientific knowledge and resources leading to a stronger foundation for advancing newborn stem cell banking and research MELBOURNE, Australia, June 3, 2021 /PRNewswire/ -- Cell Care, Australia's leading cord blood bank, today announced it has be...
2021-06-03 06:00
2196
First Patient Dosed in QBiotics & MSD Clinical Trial Collaboration for Unresectable Melanoma
* First patient dosed with QBiotics' lead oncology molecule tigilanol tiglate in combination with KEYTRUDA® (pembrolizumab) in a clinical trial collaboration with MSD (tradename of Merck & Co., Inc.,Kenilworth, NJ, USA) * The Phase Ib/IIa study will test the safety, optimal dose and tumour re...
2021-06-03 06:00
2391
Nanoform raises its mid-term business targets for 2025
HELSINKI, June 2, 2021 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), an innovative nanoparticle medicine enabling company, today announced its raised mid-term business targets for 2025. The new targets are as follows: * To nanoform annually at least 70 new active pharmaceutical ...
2021-06-02 21:42
1531
GenScript Biotech and Ligand Pharmaceuticals Enter into Global OmniAb® Licensing Agreement
NANJING, China and SAN DIEGO, June 2, 2021 /PRNewswire/ -- GenScript Biotech Corporation (HKG: 1548) along with its subsidiary, GenScript ProBio, and Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today that they have entered into a strategic licensing agreement for Ligand's OmniAb®...
2021-06-02 21:00
8940
Portonbio announced strategic cooperation with KAEDI to accelerate the R&D and production of CAR-T drugs
SUZHOU, China, June 2, 2021 /PRNewswire/ -- On May 31, 2021, Porton Biologics Ltd. (hereinafter referred to as Portonbio) announced a strategic cooperation with Nanjing KAEDI Biotech, Inc. (hereinafter referred to as KAEDI).Portonbio will offer CMC services for KAEDI's CAR-T cell therapies with i...
2021-06-02 20:10
1637
PharmAbcine to Present at the BIO Digital International Convention 2021
DAEJEON, South Korea, June 2, 2021 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of antibody therapeutics, announced today that the company will participate in BIO Digital International Convention. The company will participate in...
2021-06-02 20:00
2286
Samsung Biologics and KAHR Medical Announce Development and Manufacturing Agreement for Cancer Immunotherapy Drug Candidate
INCHEON, South Korea, June 2, 2021 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), the world's leading contract development and manufacturing organization, signed a strategic partnership with KAHR Medical Ltd., a cancer immunotherapy company developing novel multifunctional immune-recruitment...
2021-06-02 19:00
1423
CPF launches plant-based "MEAT ZERO", eyeing to make it world's Top 3 alternative meat brand in 3-5 years
BANGKOK, June 2, 2021 /PRNewswire/ -- Charoen Pokphand Foods PLC (CPF) unveils "MEAT ZERO", the meat that is made from plants and manufactured to feel, taste, and appear like real meat thanks to "PLANT-TEC" innovation. The new product, expected to appeal to health-conscious consumers, is affordab...
2021-06-02 17:40
2094
ImmVira will present the U.S. Clinical Phase I Study Results of MVR-T3011 via Intratumoral Administration at ASCO 2021
SHENZHEN, China, June 2, 2021 /PRNewswire/ -- ImmVira will present results from
its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at
the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-
8, 2021 for the first time.
2021-06-02 16:14
1276
Antengene Announces Abstracts on Twelve Clinical Studies of Selinexor Selected by EHA 2021
SHANGHAI and HONG KONG, June 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-06-02 08:00
3383
Transcenta Announced Completion of First Patient Dosing in PET-CT Imaging Study of Radionuclide-Labeled CLDN18.2 Antibody
SUZHOU, China, June 2, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced completion of first patient dosing in PET-CT imaging st...
2021-06-02 08:00
2059
Antengene Announces Fifteen Clinical Studies and Results of Selinexor to be Presented at ASCO 2021
SHANGHAI and HONG KONG, June 2, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncolo...
2021-06-02 08:00
2659
Bridge Biotherapeutics Announces the Initiation of the Proof of Mechanism Study for BBT-401 in Patients with Ulcerative Colitis; Rectal Delivery of Drug to Target Site
* The new proof of mechanism trial in ulcerative colitis had its first patient dosed inNew Zealand * In parallel with the oral-administered, proof of clinical principle study, the new proof of mechanism study will examine the efficacy of BBT-401 when delivered directly to the target organ via...
2021-06-02 06:00
1469
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
2024-11-20 16:30
7120
